Skip to main content
National Advisory Committee on Blood and Blood Products (NAC)
Main navigation
Blood Shortage
Endorsements
Guidelines & Recommendations
COVID-19 Pandemic Resources
Blood Component Transfusion Recommendations
Plasma Protein and Related Products Recommendations
Special Testing / Modification Recommendations
Adverse Event Recommendations
Archived Documents
Links & Resources
Citations
EN
FR
Open Menu
You are here
Home
Guidelines & Recommendations
Guidelines & Recommendations
COVID-19 Pandemic Resources
Infection Prevention and Control Considerations for Return of Blood Components and Products to Inventory
NAC IP & C Considerations: Appendix A COVID
Blood Component Transfusion Recommendations
Massive Transfusion Consensus Conference
NAC Companion Document to: “Red Blood Cell Transfusion: A Clinical Practice Guideline from the AABB”
NAC Patient Blood Management Statement
NAC Recommendations for the Use of Solvent-Detergent Plasma in Canada
NAC Statement on Perioperative Autologous Blood Donation
NAC Statement on the Introduction of Leukocyte Reduced Whole Blood in Canada
National Advisory Committee (NAC) on Blood and Blood Products Position Paper: Utilization and Inventory Management of Group O RH(D)- Negative Red Cells
Plasma Protein and Related Products Recommendations
Immunoglobulin Utilization Statement
NAC Statement on Clinical Equivalency of Select Fractionated Plasma Protein Products
NAC Statement on Factor XIII Concentrate Use
NAC Statement on Fibrinogen Concentrate Use in Acquired Hypofibrinogenemia
Recombinant Factor VIIa
Recommendations for Use of Prothrombin Complex Concentrates in Canada
Special Testing / Modification Recommendations
Cytomegalovirus (CMV)
Recommendations for Use of Irradiated Blood Components in Canada
RHD Genotyping in Prenatal Patients
Supplement to the NAC-CCNMT Irradiation Recommendations
Adverse Event Recommendations
Adverse Reaction Reporting Mechanisms
Canadian Transfusion Adverse Event Reporting Form
Key Messages- Sentinel Event Communication and Reporting
Questions and Answers Briefing - Bill C-17: Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)
Recommendations for the Notification of Recipients of a Blood Component Recall
